XML 57 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 35 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Sep. 30, 2018
Aug. 31, 2018
Mar. 31, 2018
Jan. 31, 2018
Jul. 31, 2017
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Jan. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Research and development                 $ 2,068     $ 4,413 $ 7,538 $ 8,024    
Other liabilities, noncurrent       $ 11,887         11,887       11,887   $ 11,117  
Sales                 10,794     10,325 31,296 29,689    
Japan                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Sales                 761     775 2,353 2,320    
United States                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Sales                 5,030     4,594 13,425 13,096    
Lynparza | Other Assets                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Finite-lived intangible assets       468         468       468      
Lenvima | Other Assets                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Finite-lived intangible assets       266         266       266      
Adempas | Other intangibles                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Finite-lived intangible assets       1,100         1,100       1,100      
AstraZeneca                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments               $ 1,600                
Payments to acquire intangible assets               $ 750             250  
Research and development                       $ 2,350   $ 2,350 2,350  
AstraZeneca | Lynparza                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Amortization expense                   $ 17 $ 9          
AstraZeneca | Sales-Based Milestones                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Probable contingent payments collaborative arrangement                   200            
Other liabilities, noncurrent           $ 150       200 150       100  
Contingent milestone payments collaborative arrangement                         3,650      
AstraZeneca | Regulatory Milestones                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments             $ 70                  
Contingent milestone payments collaborative arrangement                         1,930      
Eisai                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments           750                    
Research and development                         1,400      
Eisai | Forecast                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Payments to acquire intangible assets $ 125 $ 200 $ 325                         $ 650
Eisai | Sales-Based Milestones                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Probable contingent payments collaborative arrangement                 50              
Other liabilities, noncurrent       50         $ 50       50      
Contingent milestone payments collaborative arrangement           3,970             3,920      
Eisai | Regulatory Milestones                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Contingent milestone payments collaborative arrangement           385             160      
Eisai | Regulatory Milestones | Japan                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments           $ 25                    
Eisai | Regulatory Milestones | United States                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments         $ 125                      
Eisai | Regulatory Milestones | European Union                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments         $ 50                      
Eisai | Regulatory Milestones | China                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments       $ 25                        
Bayer AG | Adempas                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Amortization expense                   106            
Sales                             $ 500  
Bayer AG | Sales-Based Milestones                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Upfront and milestone payments                     $ 350          
Probable contingent payments collaborative arrangement                   375            
Other liabilities, noncurrent                   $ 375            
Contingent milestone payments collaborative arrangement                         $ 400